ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
Phase 1
Completed
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- Drug: Enfortumab vedotin
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 19
- Registration Number
- NCT03070990
- Locations
- 🇯🇵
Site JP00003, Tsukuba, Ibaraki, Japan
🇯🇵Site JP00005, Sendai, Miyagi, Japan
🇯🇵Site JP00008, Suita, Osaka, Japan
A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
Phase 4
Completed
- Conditions
- Restless Legs Syndrome (RLS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 375
- Registration Number
- NCT03053427
- Locations
- 🇯🇵
Site JP00025, Nagoya, Aichi, Japan
🇯🇵Site JP00029, Nagoya, Aichi, Japan
🇯🇵Site JP00040, Nagoya, Aichi, Japan
A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 334
- Registration Number
- NCT02988973
- Locations
- 🇯🇵
Site JP00009, Kasugai, Aichi, Japan
🇯🇵Site JP00030, Nagoya, Aichi, Japan
🇯🇵Site JP00051, Nagoya, Aichi, Japan
A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 100
- Registration Number
- NCT02964936
- Locations
- 🇯🇵
Site JP00007, Aichi, Japan
🇯🇵Site JP00018, Aichi, Japan
🇯🇵Site JP00028, Aichi, Japan
A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia
Phase 3
Completed
- Conditions
- Hemodialysis Chronic Kidney Disease Patients With Anemia
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 303
- Registration Number
- NCT02952092
- Locations
- 🇯🇵
Site JP00008, Aichi, Japan
🇯🇵Site JP00018, Aichi, Japan
🇯🇵Site JP00020, Aichi, Japan
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 18
- Registration Number
- NCT02952040
- Locations
- 🇯🇵
Site JP00001, Tokyo, Japan
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Phase 4
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 206
- Registration Number
- NCT02918968
- Locations
- 🇯🇵
Site JP00024, Nagoya, Aichi, Japan
🇯🇵Site JP00025, Nagoya, Aichi, Japan
🇯🇵Site JP00038, Matsuyama, Ehime, Japan
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 175
- Registration Number
- NCT02897219
- Locations
- 🇯🇵
Site JP00005, Aichi, Japan
🇯🇵Site JP00028, Aichi, Japan
🇯🇵Site JP00003, Chiba, Japan
A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-08-31
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 72
- Registration Number
- NCT02884635
- Locations
- 🇯🇵
Site JP00022, Aichi, Japan
🇯🇵Site JP00023, Aichi, Japan
🇯🇵Site JP00017, Chiba, Japan
Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 103
- Registration Number
- NCT02847091
- Locations
- 🇯🇵
Site JP00007, Gunma, Japan
🇯🇵Site JP00008, Hiroshima, Japan
🇯🇵Site JP00009, Hyogo, Japan